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ABSTRACT
Sea lice (Copepoda, Caligidae) are the most widely distributed marine pathogens in the salmon
industry. Vaccination is considered an efficient, environmentally safe and economically sustainable
alternative for control of ectoparasite infestations. Although emerging sea lice proteins have been
identified recently, and have been proposed as potential targets for generating protective molecules,
only a limited number of them have been evaluated in vaccine trials with unsuccessful results. On
the other hand, more than 80 proteins are found in eukaryotic ribosomes. The protein P0 is essential
for the assembly of the 60S ribosomal subunit and essential for cell viability. A vaccinationchallenge trial with an immunogenic peptide of Rhipicephalus sanguineus protein P0 reduced
survival of ticks with an overall efficacy of 90%, suggesting that it might be a promising antigen
candidate for the control of ectoparasite. We have identified an immunogenic region of the
ribosomal protein P0 from Caligus rogercresseyi and Lepeophtheirus salmonis that is not very
conserved compared to host P0. We developed several vaccine candidates based on this peptide and
produced in E. coli. These antigens were able to elicit a high specific antibody response after
intraperitoneal (ip) immunization using tilapia as teleost fish model. It has been shown that ip
immunization with some antigens cannot significantly reduce larval lice numbers despite enhanced
specific antibody titers were raised. In this context, we have been developed for first time several
tools to monitor tilapia immune response (IgT, IFN-γ, IL-4, CD154) to vaccination in order to
perform a more complete evaluation of the impact of the vaccinate candidates on the fish immune
system. These findings will be finally validated in an immunization-challenge trial in Salmo salar.
The overall results are relevant in the development of an effective vaccine against sea lice.
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